This study was designed to determine if a viable biodegradable three-dimensional fibroblast construct (3DFC) patch implanted on the left ventricle after myocardial infarction (MI) improves left ventricular (LV) function and blood flow. We ligated the left coronary artery of adult male Sprague-Dawley rats and implanted the 3DFC at the time of the infarct. Three weeks after MI, the 3DFC improved LV systolic function by increasing (p < 0.05) ejection fraction (37 ± 3% to 62 ± 5%), increasing regional systolic displacement of the infarcted wall (0.04 ± 0.02 to 0.11 ± 0.03 cm), and shifting the passive LV diastolic pressure volume relationship toward the pressure axis. The 3FDC improved LV remodeling by decreasing (p < 0.05) LV endsystolic and end-diastolic diameters with no change in LV systolic pressure. The 3DFC did not change LV end-diastolic pressure (LV EDP; 25 ± 2 vs. 23 ± 2 mmHg) but the addition of captopril (2mg/L drinking water) lowered (p < 0.05) LV EDP to 12.9 ± 2.5 mmHg and shifted the pressure-volume relationship toward the pressure axis and decreased (p < 0.05) the LV operating end-diastolic volume from 0.49 ± 0.02 to 0.34 ± 0.03 ml. The 3DFC increased myocardial blood flow to the infarcted anterior wall after MI over threefold (p < 0.05). This biodegradable 3DFC patch improves LV function and myocardial blood flow 3 weeks after MI. This is a potentially new approach to cell-based therapy for heart failure after MI.
INTRODUCTION
Because of these drawbacks, we have developed a different approach to cell-based therapy for heart failure; we implant a matrix graft onto the infarcted heart to Cell-based therapy with direct injection of cells into the infarcted heart is currently being examined as a new provide a support structure for new blood vessel growth (10) . This matrix provides a more hospitable environ-treatment for heart failure. While a number of different cell types have been shown to improve left ventricular ment for cell migration and growth into the damaged left ventricle. In this report we provide data on a three-(LV) function in animal models of acute ischemic damage, the results of direct cell injection into the heart in dimensional biodegradable dermal fibroblast construct (3DFC) that is a matrix-embedded human construct of clinical trials has been less dramatic (1, 3, 13, 19, (28) (29) (30) (31) (32) 36) . In part, this appears to be because few of the trans-newborn dermal fibroblasts cultured in vitro onto a bioabsorbable mesh to produce a living, metabolically ac-planted cells survive when injected into the infarcted heart (2, 14, 21, 34) . While the explanation for this is not tive tissue that has the potential to increase new blood vessel formation in vivo (15, 16) . clear, it may be that injecting cells directly into injured myocardium or scar tissue is a problem because this Our hypothesis is that the 3DFC matrix or patch graft will improve LV function and increase myocardial blood damaged tissue is not a supportive milieu (i.e., scar tissue has an inadequate blood supply with insufficient via-flow when implanted onto an infarcted heart. To test this hypothesis, we created an anterior wall myocardial ble tissue or matrix support for new cells to attach, survive, and grow). infarction (MI) by ligating the left coronary artery of 284 THAI ET AL.
rats, implanted the 3DFC patch at the time of surgery groups of rats: MI and captopril (2 g/L drinking water) and MI + 3DFC patch and captopril (2 g/L drinking wa-and used solid-state micrormanometers to measure hemodynamics, two-dimensional echocardiography to mea-ter) for 3 weeks. sure LV regional wall motion, function, chamber size,
The 3DFC Patch immunohistochemistry for microvessel density analysis, and neutron-activated microspheres to measure myocar-The 3DFC patch is a cryopreserved human fibroblastderived tissue composed of fibroblasts, extracellular ma-dial blood flow. We treated a separate group of infarcted rats with a combination of the 3DFC patch and captopril trix, and a bioabsorbable scaffold (15, 16) . Figure 1 is a scanning electron micrograph of the 3DFC showing that in order to simulate the clinically relevant situation where a patient in heart failure after a MI is treated with the vicryl fibers are "tube-like" structures. The fibroblasts look like irregular structures with long append-an angiotensin converting enzyme inhibitor. The data show that the 3DFC patch improves blood flow, regional ages that span from one vicryl fiber to another. The fibroblast cells are from a qualified cell bank, which has wall motion in the infarcted left ventricle, ejection fraction (EF), and partially reverses maladaptive LV re-been extensively tested for animal viruses, retroviruses, cell morphology, karology, isoenzymes, and tumor-modeling after MI. We do not see these results when a nonviable patch alone is placed over the infarcted myo-genicity. Reagents used in the manufacture of the 3DFC patch are tested and found free from viruses, retrovi-cardium. The addition of captopril to the 3DFC also lowers LV end-diastolic pressure (LV EDP) and shifts ruses, endotoxins, and myocoplasma before use. One piece of approximately 2 × 3 in. (5 × 7.5 cm) in size is the LV pressure-volume relationship toward the pressure axis. This study shows that placing a viable fibro-supplied frozen in a clear bag for a single-use application. The patch remains frozen at −75 ± 10°C continu-blast matrix on the infarcted myocardium may be a new approach to cell-based therapy for heart failure after ously until ready for use when it is placed in a sterile bowl containing PBS (34-37°C). The patch is handled a MI. gently by the edges to limit cellular damage and applied MATERIALS AND METHODS to the heart within 60 min of being removed from its Study Design and Treatment Groups container (Fig. 2 ). The 3DFC patch was provided by Theregen, Inc. (San Francisco, CA). To test the efficacy of the 3DFC in the treatment of To separate the effects of the cells from physical efheart failure after MI, we had five treatment groups: sham fects of the vicryl we examined the effects of nonviable (N = 14); MI (N = 18); MI + 3DFC (N = 11); MI + 3DFC 3DFC. The nonviable 3DFC is the standard 3DFC that (nonviable) (N = 12); MI + 3DFC + captopril (N = 8).
is rendered nonviable by storage for 9 or more days at Coronary Artery Ligation Experimental MI −20°C. The nonviable 3DFC consists of the same biodegradable vicryl mesh with fibroblasts and extracellular Heart failure is created in rats using standard techniques in our laboratory (8, 9, 12, 24, 26, 33) . In brief, rats matrix with matrix-bound growth factors and cytokines. The fibroblasts are killed with the higher temperature are anesthetized with ketamine and acepromazine and a left thoracotomy performed. The heart is expressed from freeze phase (−20°C), leaving behind the standard extracellular matrix (tissue) and matrix-bound proteins as the thorax and a ligature placed around the proximal left coronary artery. The heart is returned to the chest and well as the cellular debris. (8, 12) . Myocardial in-a scaffold is thought to be due to the fact that the majority of these fibroblasts show little induction of CD40 farction is confirmed by hemodynamics (LV end-diastolic pressure >16 mmHg) and presence of a scar. Prior to and HLA-DR in response to γ-interferon (17) . The 3DFC patch is FDA approved for wound healing; it has closing the chest, the 3DFC patch is engrafted onto the injured myocardium with the chest open as described been used in over 20,000 patients mostly as a skin graft for diabetic foot ulcers with no untoward complications. below. The lungs are inflated, the chest closed, and the rat allowed to recover. We treated two other separate
There is no activation of the immune system in patients treated with this patch for diabetic foot ulcers, other skin ing M-mode through the anterior wall of the left ventricle, the LV wall thickness is measured at diastole and repair, and oropharyngeal palate repair. systole; the difference in the thickness between the two Hemodynamic Measurements measurements is the systolic displacement. This is a useful measurement to quantify focal LV wall systolic func-We measure hemodynamics using methods reported previously by our laboratory (9, 10, (24) (25) (26) 33) . In brief, tion. rats are anesthetized with inactin (100 mg/kg IP injection) and placed on a specially equipped operating table
Myocardial Perfusion with a heating pad to maintain constant body tempera-We use neutron activated microspheres (BioPal Inc, ture. Following endotracheal intubation and placement Worcester MA) to measure myocardial blood flow. The on a rodent ventilator, a 2F solid state micromanometer isotopes are injected, a tissue sample obtained, and at a tipped catheter with two pressure sensors (Millar) is inlater time activated with the emitted radiation measured serted via the right femoral artery, with one sensor lowith high-resolution detection equipment (7, 18, 27) . cated in the left ventricle and another in the ascending With this system, BioPal, Inc. provides the isotopes and aorta. The pressure sensor is equilibrated in 37°C saline tissue containers. Three separate isotopes (lutetium, gold, prior to obtaining baseline pressure measurements. After and samarium) are injected in each rat: one at baseline a period of stabilization, LV and aortic pressures, and prior to coronary ligation, one immediately after ligaheart rate are recorded and digitized at a rate of 1000 tion, and one at the endpoint of the study. Because dif-Hz using a PC equipped with an analog-digital converter ferent rats are used for each group we are able to obtain and customized software. From these data, LV dP/dt is end point data after different treatments (MI at 3 weeks, calculated.
MI at 3 weeks + 3DFC). For each measurement 750,000 nonradioactive elementally labeled 15-µm microspheres LV Pressure-Volume Relationships (V = 300 µl) from Biopal, Inc. are injected into the left The LV pressure-volume relationship is measured as ventricle transapically with a 1-cc syringe and 27-gauge outlined in our previous work (8, 12) . In brief, the heart needle. At the terminal study point, the tissues are haris arrested with potassium chloride, and a catheter convested, oven dried, and collected for analysis. At the sisting of PE-90 tubing with telescoped PE-10 tubing time of microsphere injection we perform a transthoracic inside is inserted into the LV via the aortic root. One echocardiogram to measure stroke volume. By knowing end of the double-lumen LV catheter is connected to a the heart rate, we calculate cardiac output as stroke volvolume infusion pump (Harvard Apparatus) while the ume × heart rate. Assuming 4% of the cardiac output other end is connected to a pressure transducer zeroed perfuses the coronary arteries (27), we know the total at the level of the heart. The right ventricle is partially myocardial blood flow; the number of microspheres deincised to prevent loading on the LV. The LV is filled posited in the anterior wall is percentage of blood flow (1.0 ml/min) to 60-100 mmHg and unfilled while presdown the left coronary artery to the anterior wall at each sure is recorded onto a physiologic recorder (Gould). time point. Ischemic time is limited to 10 min. Volume infused is a function of filling rate. Histopathology
Hearts were formalin fixed (10%) prior to paraffin Echocardiography embedding. HIER antigen retrieval of 3-µm-thick sec-We perform closed chest transthoracic echocardiogrations was performed in citrate-based Diva buffer (pH phy at baseline prior to the MI, immediately after MI, 6.2) for 1 min at 125°C using a "Decloaker" pressure and at 3 weeks after MI using methods previously develcooker (Biocare Medical Concord, CA). We used single oped in our laboratory (33) . We use a Vingmed, Vivid immunohistochemical staining for anti-rabbit factor VIII 7 system echo machine (GE Ultrasound) with EchoPac (Dako) (1:1000) to perform histological analysis of mi-(GE Ultrasound) programming software with a 10 MHz crovessel density. multiplane transducer with views in the parasternal short axis and long axis, to specifically evaluate the anterior, Vessel Density lateral, anterolateral, inferior, and posterior walls. Twodimensional (2D) and M-mode measurements of myo-We defined vessel density by light microscopy at 40× magnification. The number of cross section vessels per cardial wall thickness and LV dimensions are obtained throughout the cardiac cycle and are used for calculation field was counted by two persons blinded to treatment. Average measurements from six different fields were re-of systolic displacement of the anterior wall, ejection fraction, and regional fractional shortening. Systolic dis-corded for each value. Knowing the area of the optical field, data are reported as number of vessels/µm 2 . placement is a measure of focal LV wall thickening. Us-
Statistical Analysis
2.3 ± 3.7 to 9.1 ± 1.9 mmHg/ml/min; compared to acute MI, vascular resistance in chronic heart failure was un-Data are expressed as mean ± SE. For the physiologic changed at 7.7 ± 0.92 mmHg/ml/min. The 3DFC deand echocardiographic measurements, the effects of the creased (p < 0.05) vascular resistance to 3.9 ± 0.86; the 3DFC were determined by using two-way analysis of addition of captopril further decreased (p < 0.05) vascuvariance followed by the Student t-test. The value of p < lar resistance to 0.41 ± 0.03 mmHg/ml/min. 0.05 was accepted as significant. The authors had full access to the data and take responsibility for its integrity.
Echocardiographic Changes in LV Function All authors have read and agree to the manuscript as and PV Loops written.
The data on global and regional changes in LV func-RESULTS tion are seen in Figures 3, 4 , 5, and 6. There was a In Vivo Hemodynamics decrease (p < 0.05) in LV EF (75 ± 4% to 37 ± 3%) with the acute MI and a subsequent increase (p < 0.05) Rats with MI had a fourfold increase in left ventricular end diastolic pressure, a 22% reduction in LV sys-with the 3DFC patch (53 ± 4%). The EF did not increase with the nonviable 3DFC (31 ± 2%); the addition tolic blood pressure, a 24% reduction in mean arterial blood pressure, a 37% reduction in left ventricular dP/ of captopril to the 3DFC did not change the EF compared to 3DFC alone (48 ± 3%). The changes in regional dt, and a 21% prolongation of the time constant of LV relaxation or tau (Table 1) . The baseline data are consis-LV function, defined as systolic displacement calculated from parasternal short axis M-mode echocardiography, tent with our previous reports using this model showing that ligation of the left coronary artery results in a large were similar. With the coronary ligation, there was a decrease (p < 0.05) in systolic displacement of the ante-anterior wall MI and heart failure with a decrease in LV systolic function, an elevation of LV EDP, and a rior infarcted wall (0.15 ± 0.03 to 0.05 ± 0.02 cm) with a return toward normal with the placement of the 3DFC prolongation of tau (8, 9, 12, [24] [25] [26] 33) . The 3DFC lowered (p < 0.05) mean arterial pressure and increased patch (0.11 ± 0.04 cm). The nonviable 3DFC did not alter EF or systolic displacement. (p < 0.05) peak developed pressure or PDP (126 ± 4 to 146 ± 8 mmHg).
The LV end-diastolic diameter increased (p < 0.05) from 4.6 ± 0.4 to 8.1 ± 0.3 mm and the LV end-systolic Captopril Treatment diameter increased (p < 0.05) from 1.2 ± 0.2 to 4.1 ± 0.7 mm 3 weeks after MI (Fig. 5 ). The 3FDC patch de-Treatment with captopril after MI lowered (p < 0.05) MAP, LV SP, and LV EDP; these changes are similar creased (p < 0.05) LV end-diastolic diameter to 6.6 ± 0.4 mm and end-systolic diameter to 1.8 ± 0.08 mm. The to what we and other investigators have previously shown (26). The addition of captopril in the 3DFC rats PV relationship shows dilatation of the ventricle with the MI but no shift when the 3DFC patch was added lowered LV EDP from 23 ± 2 to 13 ± 3 mmHg and PDP from 146 ± 8 to 123 ± 5 mmHg (p < 0.05); all other he- (Fig. 6 ). The addition of captopril to the 3DFC shifted the PV loop to the left toward the pressure axis and de-modynamic parameters were unchanged (Table 1) . Vascular resistance increased (p < 0.05) with acute MI from ceased the operating LV end-diastolic volume from 0.57 ± 0.05 to 0.34 ± 0.03 ml (p < 0.05). The nonviable 3DFC DISCUSSION did not alter end-diastolic or end-systolic diameter.
The important findings in this study are that this Increased Blood Vessels and Myocardial Blood Flow three-dimensional biodegradable fibroblast patch increases myocardial blood flow in the damaged region of With acute MI, there was an approximately 80% decrease in blood flow to the infarcted wall, which was the LV and increases systolic displacement in the anterior infarcted wall after an acute MI. The 3DFC reverses not altered at 3 weeks. With the 3DFC, the blood flow increased to about 70% of baseline (Fig. 7) . The increase maladaptive LV remodeling, by increasing EF and decreasing LV end-diastolic and end-systolic diameters. in blood flow was a result of new blood vessel formation with the 3DFC (Figs. 8 and 9 ).
The addition of captopril lowers LV end-diastolic pres- sures and decreases the operating LV end-diastolic vol-ing that at 1 year, bone marrow cell injection with a higher percentage of CD34 + cells decreases reinfarctions ume. These data support our hypothesis that this viable fibroblast patch provides a supporting structure for the and revascularization procedures with revascularizations driving an improved composite end-point of revascu-damaged heart and may be an alternative to direct cell injection for cell-based therapy for heart failure after MI. larizations, MI, and death (30) . We believe that this general lack of positive results with direct cell injection is Cell-Based Therapy for Heart Failure due in part to the observation that most of these newly injected cells do not survive chronically in the infarcted While the original animal data with cell-based therapy for heart failure were very encouraging, the results heart and do not transdifferentiate into cardiac myocytes (2,21,34). Investigators are now injecting cardiac stem from the most recent clinical trials with direct cell injection into the heart and/or coronary arteries have been cells into the heart in an attempt to obviate the need for stem cells to transdifferentiate (23). disappointing. Clinical trials such as the BOOST, TOPCARE, the IACT, the REPAIR-MI, the ASTAMI Three-Dimensional Fibroblast Patch Trial, and a bone marrow transplant study from Belgium of intracoronary delivery of autologous bone marrow Our hypothesis is that the lack of survival of new cells directly injected into the heart is related, in part, to cells in patients after MI with PCI show only modest improvement in LV function, mostly in patients with an inadequate blood supply and inadequate matrix support for the new cells. The injected cells are fragile, re-preserved EFs with some questions about delivery techniques (1,3,13,19,23,28-32,36) . The most positive re-sulting in cell aggregation due to lack of physical support for the cells to attach to the tissue extracellular sults are a subset analysis of the REPAIR-MI trial show- matrix. This three-dimensional scaffold offers a poten-providing a new support structure for the damaged heart, we also need to create a mature blood supply such that tial solution to the problem of an inadequate support structure. While injection of passive materials has been new viable cardiac muscle can be organized in parallel forming physical and neural connections that will con-proposed to improve EF potentially by decreasing wall stress (11, 35) , the 3DFC provides a viable cell matrix duct electrical signals and create synchronized contractions. Investigators have proposed that the ideal scaffold that supports new blood vessel growth (15, 16) . This viable cellular matrix is important because in addition to structure for the heart would consist mainly of highly interconnected pores with a diameter of at least 200 µm, blood vessel growth has been documented previously in SCID mice (15) . the average size of a capillary, to permit blood vessel penetration and cell interactions (5) .
Previous work using the 3DFC as a patch for the infarcted heart in SCID mice showed histological evidence The 3DFC is a viable construct composed of a matrix embedded with human newborn dermal fibroblasts cul-of new blood vessel growth and improvements in global LV function using a conductance catheter (16) . Our data tured in vitro onto a bioabsorbable mesh to produce living, metabolically active tissue (15, 16) (see Figs. 1 and show increases in myocardial blood flow in the infarcted heart, confirming that these blood vessels are functional 2). As the fibroblasts proliferate across the mesh, they secrete human dermal collagen, fibronectin, and glyco-and that they connect to the native myocardium. We used echocardiography to document improvements in saminoglycans (GAGs), embedding themselves in a selfproduced dermal matrix. The fibroblast cells produce global and regional LV function. The improvements in regional LV function are important because recent work angiogenic growth factors: vascular endothelial growth factor (VEGF), hepatocyte growth factor (HGF), basic suggests that the injection of passive materials alone may be enough to reduce wall stress and increase global fibroblast growth factor (bFGF), and angiopoietin-1. The construct is grown in medium supplemented with EF (35). In order to prove that cell-based therapy is affecting more than a passive response, the point has been serum and ascorbate; at harvest, the medium is replaced with a 10% DMSO-based cryoprotectant, the tissue is made that it is necessary to be able to define regional changes in the area of the infarcted myocardium (11) . frozen and stored at −70°C. This cryopreservation and rewarming technique has been extensively studied to en-We have done this using echocardiography to document that the 3DFC increases systolic displacement of the in-sure viability of the patch. Although the mechanisms of action of the 3DFC are not completely understood, new farcted regional anterior wall (Fig. 5 ). Although the mechanism of action of the 3DFC has not been com-a area of viable myocardium. This trial is designed to determine if the 3DFC increases myocardial perfusion pletely delineated, the viable fibroblasts secrete a number of growth factors, thus providing a paracrine effect to an area that the surgeon could not graft. While in this clinical study the 3DFC patch is placed with the chest to stimulate new blood vessel growth. The vicryl mesh is biodegradable such that, with dissolution, the new open, two cases have been done with a minimally invasive approach using a modified video-assisted thoras-blood vessel growth is in the previously damaged myocardium. The most likely explanation for the improve-copic surgery VATS procedure. The second trial is in patients getting a left ventricular assist device (LVAD). ments in regional systolic displacement of the anterior wall is that the increases in myocardial blood flow in The 3DFC is applied at the time of LVAD placement and, upon LVAD removal, histology is done on the area the border zone results in recruitment of hibernating or stunned cardiac myocytes.
of 3DFC placement in order to examine for evidence of angiogenesis. The fact that the 3DFC is viable with fibroblasts implanted on a mesh is important. There are data showing that inert biodegradable patches are beneficial in treating Summary heart failure. In our laboratory we have shown that an
We report improvements in myocardial blood flow, inert biodegradable collagen patch placed on the rat regional and global LV function, and partial reversal of heart after a nontransmural MI improves LV function LV remodeling using a viable three-dimensional fibroand prevents adverse LV remodeling (10) . There are blast patch implanted in rats at the time of an acute MI. clinical trials with a collagen type 1 matrix seeded with This patch provides a support structure that allows cells autologous bone marrow cells in patients undergoing to grow into the damaged heart and creates new blood coronary artery bypass surgery (4). The best known imvessel growth, resulting in improved blood flow. With planted mechanical constraint device is the Acorn Corp the limited success of direct cell injection into the heart, Cap device; it decreases LV size but does not cause conthe 3DFC represents a new approach to cell-based therstrictive physiology (22) . There are no blood flow studapy for heart failure. ies with the Acorn device. There is a recent report using interests: Theregen, Inc. provided the 3DFC patch but did not provide any financial support for these studies. The University Application of a Patch as an Alternative of Arizona has a licensing agreement with Theregen to use the to Direct Cell Injection 3DFC patch in the heart. Drs. Thai, Kellar, and Goldman are The use of a biodegradable patch that provides a supconsultants for Theregen and Dr. Williams is on the Advisory Board for Theregen. port structure allowing new cells to attach and grow in a damaged heart is a possible alternative to the current REFERENCES approach of direct cell injection for cell-based therapy. 
